NEW YORK, Dec. 11 /PRNewswire/ -- InterCure, Ltd. (Tel Aviv Stock Exchange: INCR) manufacturer of the RESPeRATE(R) hypertension treatment device, clinically-proven to significantly lower blood pressure, today announced the appointment of Scot Dube as Vice President of Sales. Dube brings more than 30 years of medical device and consumer product leadership to InterCure and will be a driving force as InterCure launches RESPeRATE into retail channels.
Prior to joining InterCure, Dube served as President of Microlife, USA, Inc., the U.S. subsidiary of Microlife Corporation, the Taiwanese-based international leader in the marketing and distribution of medical diagnostic products including blood pressure monitors, infrared and digital thermometers, peak flow meters and weight management devices. During his 10 years at Microlife, Dube successfully re-engineered the U.S. business from an OEM manufacturer to a leading direct-to-retail brand, driving growth through Wal-Mart, Costco, Walgreens, CVS and other key retailers. Under his leadership, Microlife’s blood pressure monitoring business grew 15 share points in one year, garnering the number two share in the category. Prior to Microlife, Dube served as national sales and marketing manager for Florida Medical Industries, directing sales and marketing activities for both consumer diagnostic and therapeutic medical products. Dube also held sales and marketing positions of increasing responsibility at Becton Dickinson, Travenol Labs and Schering Laboratories.
“Scot’s leadership within the consumer medical device industry -- and the hypertension market in particular -- coupled with his outstanding record of success in building sustained profitable growth within retail channels will be instrumental for RESPeRATE,” said Erez Gavish, president and CEO of InterCure. “Scot will serve as a catalyst for expanding InterCure’s retail presence and represents the last key piece of our world class sales and marketing organization. We are pleased to welcome Scot as a member of our executive management team.”
“Having navigated the consumer healthcare market for three decades, I believe InterCure is uniquely positioned to tap the enormous growth occurring within the Personal Therapeutic Device category,” said Scot Dube, new Vice- President of Sales, InterCure. “Retailers are actively seeking opportunities to drive incremental profit through new category evolution. I look forward to expanding InterCure’s market position as both the innovator and leader in the important hypertension treatment market. Hypertension is reaching epidemic proportions in the United States and around the globe, and the need for effective treatments could not be greater. I look forward to leveraging my extensive sales and marketing management experience to launch and promote retail distribution, bringing the RESPeRATE device to store shelves across America.”
About RESPeRATE
RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body’s natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a “therapeutic zone” of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.
About InterCure, Ltd.
InterCure, a medical device company, publicly traded on the Tel Aviv Stock Exchange (TASE: INCR) has become a leader in the growing Personal Therapeutic Device category. Its broadly patented “device-guided breathing” technology platform enables a systematic reduction in sympathetic outflow of the autonomic nervous system. InterCure is successfully selling the world’s first hypertension treatment device, RESPeRATE(R), with more than 75,000 units sold. With multiple published clinical studies, regulatory clearance in most key international markets (including FDA over-the-counter (“OTC”) clearance in the U.S., the European CE mark and the Chinese SDA among others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (www.intercure.com)
Forward-Looking Statements
This news release may contain forward-looking statements that are based on the Company’s current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
intercure@schwartz-pr.com bpackard@intercure.com
CONTACT: Brian Packard of InterCure, Inc., +1-646-652-5800, ext. 7134,
bpackard@intercure.com; or Lisa Mokaba of Schwartz Communications for
InterCure, Ltd., +1-781-684-0770, intercure@schwartz-pr.com
Web site: http://www.intercure.com/
